Search research articles
Contact Us
Filters
Showing results (31-40 of 173) with videos related to
Page
of 18
Sort By:
Cancer Metastasis Reviews
|
October 23, 2012
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma
Cindy Neuzillet, Pascal Hammel, Annemilaï Tijeras-Raballand, et al.
Future Oncology (London, England)
|
February 1, 2019
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
Juan W Valle, Ivan Borbath, Brad Rosbrook, et al.
Bulletin Du Cancer
|
July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]
Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Cancer Treatment Reviews
|
October 7, 2014
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors
Juan W Valle, Sandrine Faivre, Richard A Hubner, et al.
Targeted Oncology
|
August 23, 2012
New treatment options with cytotoxic agents in neuroendocrine tumours
Pascal Hammel, Olivia Hentic, Cindy Neuzillet, et al.
Expert Opinion on Investigational Drugs
|
June 24, 2010
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sébastien Albert, Maria Serova, Chantal Dreyer, et al.
Bulletin Du Cancer
|
September 13, 2007
[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]
Marie-Paule Sablin, Christophe Le Tourneau, Ghassan El Maalouf, et al.
Cancer Metastasis Reviews
|
May 22, 2013
Stromal expression of SPARC in pancreatic adenocarcinoma
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Jérôme Cros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells
Florence Koeppel, Virginie Poindessous, Vladimir Lazar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 28, 2014
Resistance to human epidermal growth factor receptor type 2-targeted therapies
Jean-Christophe Thery, Jean-Philippe Spano, David Azria, et al.
Page
of 18
Search research articles
Search
Showing results (31-40 of 173) with videos related to
Sort By:
Page
of 18
Cancer Metastasis Reviews
|
October 23, 2012
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma
Cindy Neuzillet, Pascal Hammel, Annemilaï Tijeras-Raballand, et al.
Future Oncology (London, England)
|
February 1, 2019
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
Juan W Valle, Ivan Borbath, Brad Rosbrook, et al.
Bulletin Du Cancer
|
July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]
Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Cancer Treatment Reviews
|
October 7, 2014
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors
Juan W Valle, Sandrine Faivre, Richard A Hubner, et al.
Targeted Oncology
|
August 23, 2012
New treatment options with cytotoxic agents in neuroendocrine tumours
Pascal Hammel, Olivia Hentic, Cindy Neuzillet, et al.
Expert Opinion on Investigational Drugs
|
June 24, 2010
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sébastien Albert, Maria Serova, Chantal Dreyer, et al.
Bulletin Du Cancer
|
September 13, 2007
[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]
Marie-Paule Sablin, Christophe Le Tourneau, Ghassan El Maalouf, et al.
Cancer Metastasis Reviews
|
May 22, 2013
Stromal expression of SPARC in pancreatic adenocarcinoma
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Jérôme Cros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells
Florence Koeppel, Virginie Poindessous, Vladimir Lazar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 28, 2014
Resistance to human epidermal growth factor receptor type 2-targeted therapies
Jean-Christophe Thery, Jean-Philippe Spano, David Azria, et al.
Page
of 18